Could a diabetes drug boost success of heart procedure for AFib patients with extra heart fat?
NCT ID NCT07331727
First seen Jan 12, 2026 · Last updated May 04, 2026 · Updated 21 times
Summary
This study tests whether dapagliflozin, a drug typically used for diabetes, can help prevent atrial fibrillation from coming back after a heart ablation procedure. The trial focuses on people with persistent AFib who have increased epicardial adipose tissue (fat around the heart) but do not have diabetes, heart failure, or kidney disease. About 280 participants will receive dapagliflozin or a placebo around the time of their ablation, and researchers will monitor heart rhythm using ECG patches for 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.